Screener
ImmunityBio, Inc. IBRX Gross margin
Gross margin at other companies
Other financials
Where this comes from
Calculated from ImmunityBio, Inc.’s reported figures.
Based on trailing twelve months.
The source filing: ImmunityBio, Inc.’s 10-Q, filed May 7, 2026. Open the filing →
- Filed
- May 7, 2026, 7:37 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001326110-26-000059
FAQ
- What is ImmunityBio, Inc.'s gross margin?
- ImmunityBio, Inc. (IBRX) reported gross margin of 99.3% in Q1 2026.
- How has ImmunityBio, Inc.'s gross margin changed year-over-year?
- ImmunityBio, Inc.'s gross margin decreased by 0.5% year-over-year, from 99.8% to 99.3%.
- What is the long-term trend for ImmunityBio, Inc.'s gross margin?
- Over 3 years (2022 to 2025), ImmunityBio, Inc.'s gross margin has grown at a -0.2% compound annual growth rate (CAGR), from 100% to 99.3%.
- What does gross margin mean?
- Gross profit (revenue minus cost of revenue) as a percentage of revenue, on a trailing-twelve-month basis. Measures how much of each sales dollar survives the direct cost of producing the goods or services sold.
Ask your AI about ImmunityBio, Inc.'s gross margin.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude